

# Tislelizumab for treating advanced non-small-cell lung cancer after platinum- based chemotherapy (terminated appraisal)

Technology appraisal guidance

Published: 19 June 2025

[www.nice.org.uk/guidance/ta1072](https://www.nice.org.uk/guidance/ta1072)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. BeiGene has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for treating in this indication.

## Information

If NHS organisations wish to consider tislelizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7065-0